TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06929273: A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania With Mixed Features in Bipolar-I Disorder (BALSAM-3)

Sponsor: Bristol-Myers Squibb · Phase: PHASE3 · Area: RARE_ORPHAN · Target Enrollment: 450 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$877,560

Rescue Site Savings

+$585,040

Unlock Full NCT06929273 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06929273 Rescue Dossier →